The evidence is based on few case series which enrolled few patients. Although this drug has shown promising results at inducing temporary partial responses in up to 35% of patients treated for Kaposi's Sarcoma, the populations studied are heterogeneous, present severe forms and there is no comparative group for analysis. Its effectiveness regarding overall survival and disease free survival remains unknown. At present, the treatment of choice still is antiretroviral therapy (HAART), and chemotherapy with vinca alkaloids, liposomal anthracyclines or paclitaxel for the more aggressive forms. Controlled studies are clearly needed to determine the drug effectiveness for sarcoma. In spite of the lack of evidence, it could be considered as a last resource treatment for patients with severe visceral involvement and poor response to standard treatment. Its assessment in other types of sarcoma is anecdotal.
